دورية أكاديمية
أعرض في EDS

SARS-CoV-2 infection in pregnant patients on TNFα inhibitor: Real-life data with a review of literature.

التفاصيل البيبلوغرافية
العنوان: SARS-CoV-2 infection in pregnant patients on TNFα inhibitor: Real-life data with a review of literature.
المؤلفون: Yu Y; Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China; Reproductive Medicine Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310002, China. Electronic address: yiqi.yu@zju.edu.cn., Pan J; Department of Obstetrics and Gynecology, Xianju County People's Hospital, Taizhou, Zhejiang 317399, China., Zhao Y; Center for Reproductive Medicine, Department of Obstetrics, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China., Guo X; Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China; Reproductive Medicine Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310002, China., Yu W; Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China., Zhou F; Center for Reproductive Medicine, Department of Traditional Chinese Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China., Shu J; Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China; Reproductive Medicine Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310002, China., Huang Q; Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China. Electronic address: huangqiongxiao@hmc.edu.cn.
المصدر: Journal of reproductive immunology [J Reprod Immunol] 2024 Jun; Vol. 163, pp. 104220. Date of Electronic Publication: 2024 Feb 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Ireland NLM ID: 8001906 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7603 (Electronic) Linking ISSN: 01650378 NLM ISO Abbreviation: J Reprod Immunol Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier/North-Holland Biomedical Press
Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/immunology , SARS-CoV-2*/immunology , Tumor Necrosis Factor-alpha*/antagonists & inhibitors , Tumor Necrosis Factor-alpha*/immunology , Pregnancy Complications, Infectious*/drug therapy , Pregnancy Complications, Infectious*/immunology , Pregnancy Complications, Infectious*/epidemiology , Pregnancy Complications, Infectious*/virology, Humans ; Pregnancy ; Female ; Adult ; Pregnancy Outcome ; China/epidemiology ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor Inhibitors/adverse effects ; Retrospective Studies
مستخلص: Tumor necrosis factor alpha (TNFα) is involved in the occurrence of negative pregnancy outcomes. The study aimed to evaluate the safety and efficacy of the immunosuppressive TNFα inhibitors (TNFαi) in the treatment of patients with a history of recurrent reproductive failure in the context of COVID-19 pandemics. We reviewed 85 patients who received TNFαi (certolizumab pegol) during Mainland China's first wave of COVID-19 pandemic, from 21st Nov 2022-11 th Jan 2023. We also collected corresponding data from 130 pregnant patients who never used TNFαi for comparison. There were no significant differences in the history of previous pregnancy loss, miscarriage, embryo implantation failure, comorbidities and doses of COVID-19 vaccination. 82.2% and 87.7% pregnant patients contracted primary COVID-19 with symptoms in TNFαi group and no-TNFαi group. Duration of symptoms was significantly longer in TNFαi group and the incidences of cough and lethargy was significantly higher in TNFαi group. Both groups reported similar severity to same-aged close contacts, similar rates of other symptoms and hospitalization. No deaths were reported. In the in vitro fertilization (IVF) subgroup, we achieved a biochemical pregnancy loss rate of 17.4%, miscarriage rate of 21.7%, ongoing pregnancy rate and live birth rate of 34.2%. COVID-19 did not influence the live birth rate. We concluded that TNFαi administration in pregnancy was not associated with increased susceptivity to and severity of COVID-19. However, TNFαi users showed more prominent symptoms and longer recovery time. The pregnancy outcomes with TNFαi in such high-risk group for pregnancy loss was satisfactory.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jing Shu reports financial support was provided by General Research Program for Medicine and Health of Zhejiang Province.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: COVID-19; SARS-CoV-2; TNFα inhibitors; autoimmune; certolizumab; pregnancy
المشرفين على المادة: 0 (Tumor Necrosis Factor-alpha)
0 (Tumor Necrosis Factor Inhibitors)
تواريخ الأحداث: Date Created: 20240306 Date Completed: 20240601 Latest Revision: 20240613
رمز التحديث: 20240613
DOI: 10.1016/j.jri.2024.104220
PMID: 38447289
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7603
DOI:10.1016/j.jri.2024.104220